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Abstract 
For a long time, the study of the HCV infectious cycle has been a major challenge for 
researchers because of the difficulties in generating an efficient cell culture system leading to 
a productive viral infection. The development of HCVpp and later on HCVcc model allowing 
for functional studies of HCV in cell culture completely revolutionized HCV research. The 
aim of this review is to provide the reader with a brief overview of the development of these 
two models. We describe the advantages of each model as well as their limitations in the 
study of the HCV life cycle, with a particular emphasis on virus entry. A comparison between 
these two models is presented in terms of virion composition and their use as tools for the 
characterization of entry factors, envelope glycoproteins functions and antibody 
neutralization. We also compare the production and biosafety level of these two types of viral 
particles. Globally, this review provides a general description of the most adequate 
applications for HCVpp and HCVcc in HCV research. 
 
 
1 Introduction 
The identification of HCV genome, which was reported for the first time in 1989 [1], 
led to a new era in molecular and biochemical research on HCV. However, for a long time it 
remained impossible to propagate HCV in cell culture and this limited the understanding of 
virus-host interactions at the cellular and molecular levels. To circumvent these limitations, 
several groups have tried to develop surrogate models to study HCV entry or replication. 
Before the development of a cell culture system for HCV (HCVcc) in 2005 [2–4], selectable 
replicon systems [5] and retrovirus-based pseudotyped particles (HCVpp) [6–8] were major 
tools used to investigate HCV genomic replication and virus entry, respectively. In this 
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review, we briefly present HCVpp and HCVcc systems and we discuss the similarities and 
differences between these two systems. 
 
1.1 The HCVpp system 
The development of the HCVpp system enabled for the first time to functionally 
investigate HCV entry. This model is based on the production of retroviral capsid particles, 
which incorporate in their lipid envelope unmodified HCV glycoproteins E1 and E2. This 
system was first described in 2003 by two different groups [6, 8] and since then it has been 
extensively used to investigate the mechanisms of HCV entry and characterize antibody 
neutralization. 
HCVpp are generated through the co-transfection of 293T cells with three plasmids 
respectively coding for (i) a retroviral genome expressing a reporter gene, (ii) the gag-pol 
proteins from human immunodeficiency virus (HIV) or murine leukemia virus (MLV) and 
(iii) HCV E1 and E2 glycoproteins. The presence of a reporter gene, such as GFP or 
luciferase, allows for the quantification of pseudoparticle entry into target cells (Figure 1). 
Even if HCV morphogenesis strongly differs from retroviral/lentiviral assembly and 
the cell surface is supposed to be the main location where retrovirus/lentivirus budding 
occurs, retroviral assembly has also been observed in the late endosomes/multi-vesicular 
bodies [9]. Moreover, overexpression of the HCV envelope glycoproteins in 293T cells leads 
to the export of a fraction of these proteins at the plasma membrane, which otherwise are 
retained in the endoplasmic reticulum [6–8]. Both these observations can explain the 
production of retroviral/lentiviral pseudoparticles containing HCV glycoproteins. The 
presence of HCV envelope proteins at the surface of HCVpp mediates interactions with HCV-
specific cellular entry factors as well as fusion with host membranes, whereas the following 
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steps are mediated by the retroviral/lentiviral components of this chimeric particle. Therefore, 
HCVpp mimic HCV entry independently of the other steps of the HCV life cycle. 
 
1.2 The HCVcc system 
After the identification of HCV genome in 1989 [1] and its characterization [10], the 
development of a cell culture system for this virus has been a slow process involving several 
crucial steps, which started with the identification of the 3’ non-coding region of the genome 
[11]. This led to the construction of full-length cDNA clones of genotype 1a that were 
transcribed in vitro and tested for viral production. However, faced with a lack of replication 
in cell culture, productive viral replication had to be validated by intrahepatic inoculation of 
chimpanzees with genomic RNA generated in vitro, after the construction of a consensus 
clone [12, 13]. These in vivo experiments encouraged the scientific community to continue 
the search for in vitro replication models. 
The first development of a functional in vitro system for HCV replication appeared in 
1999, with the construction of the first sub-genomic replicon of genotype 1b [5]. This 
subgenomic replicon is characterized by a bi-cistronic construct containing an internal 
ribosome entry site (IRES) from encephalomyocarditis virus (EMCV). In this system, the 
HCV IRES controls the expression of neomycin phosphotransferase as a selection gene, while 
the EMCV IRES drives the expression of HCV non-structural (NS) proteins from NS3 to 
NS5B. All genes are under the control of a T7 promoter, necessary for the in vitro RNA 
transcription with a T7 RNA polymerase, in order to generate the viral RNA that once 
electroporated in Huh7 cells can give rise to self-replication [5]. The addition of G418 allows 
for the selection of Huh-7 cells electroporated with the viral RNA, in order to isolate cellular 
clones replicating HCV. The development of the subgenomic replicon system enabled the 
	 5	
study of HCV replication, leading to the identification of viral proteins as well as cellular 
proteins participating in this step of the viral life cycle.  
Replication represents an important step during the viral life cycle and it is an 
interesting target for the identification of antiviral compounds. Therefore, the establishment of 
subgenomic replicons gave a great impulse to the development of antiviral drugs directed 
against non-structural proteins. The currently used direct acting antivirals (DAAs), mainly 
targeting NS3, NS5A and NS5B, were validated in vitro on subgenomic replicons (reviewed 
in [14]). 
After the assembly of functional subgenomic replicons, full-length genomes were 
reconstituted based on functional replicons. Unfortunately, transfection of hepatoma cells 
with such full-length replicons still did not lead to virion production [15–18]. This is due to 
the fact that efficient amplification of these replicons required replication enhancing 
mutations that impaired virus assembly [19]. Indeed, in addition to structural components, 
HCV non-structural proteins are also involved in virion assembly [20]. 
A major breakthrough in the development of a cell culture system for HCV came with 
the construction of a genotype 2a subgenomic replicon which replicated with very high 
efficiency without the requirement of adaptive mutations [21]. This subgenomic replicon was 
cloned from a Japanese patient suffering from a fulminant hepatitis and it was designated 
“Japanese fulminant hepatitis 1” (JFH1) virus [22]. Later on, three groups reported that the 
complete wild-type JFH1 genome or chimeras consisting of the JFH1 replicase genes NS3-
NS5B and Core to NS2 regions of alternative HCV genomes replicated efficiently in Huh-7 
cells and produced infectious viral particles [2–4]. These particles were designated HCVcc for 
cell culture-derived HCV, and they are now routinely used to study each step of the viral life 
cycle (Figure 1). During the following years, this system was further optimized thanks to the 
selection of adaptive mutations, which strongly increased the viral titers of the released 
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virions [23–25]. 
 
2 Differences in virion composition between HCVpp and HCVcc 
HCVcc particles are composed of the single-stranded RNA genome interacting with 
the core protein to form the nucleocapsid that is surrounded by a cell-derived lipid membrane 
in which the envelope glycoproteins E1 and E2 are anchored. In addition, HCV particles also 
contain host-derived components. Indeed, a specific feature of HCV virion is its interaction 
with very-low density lipoproteins (VLDL) or low-density lipoproteins (LDL), resulting in 
the formation of a lipo-viro-particle [26]. As a consequence, apolipoproteins such as apoE, 
apoB, apoA1 and apoC1 can also be found in association with HCVcc particles [27–29]. In 
addition, neutral lipids such as triglycerides and cholesteryl esters are also incorporated into 
HCVcc virions [28]. However, differences in densities between HCVcc and serum-derived 
virions suggest that the lipid composition of HCVcc does not totally reflect that of native viral 
particles [30]. 
The composition of HCVpp is very different from that of HCVcc. Indeed, the only 
HCV-specific components of HCVpp are the envelope glycoproteins, which are anchored in a 
host-derived membrane. The rest of the particle is composed of the retroviral/lentiviral core 
proteins as well as a packaging-competent retrovirus/lentivirus-derived genome harboring a 
marker gene. Therefore, only entry functions attributed to HCV envelope glycoproteins can 
be investigated with the HCVpp system. Furthermore, because of their production in kidney 
cells and their mode of assembly, HCVpp are not associated with lipoproteins, typically 
synthesized in hepatic cells. Moreover, ApoE is not found to be associated with HCVpp [31]. 
This therefore represents a major limitation for investigating the role of lipoprotein or lipid 
receptors in HCV entry. 
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Differences in maturation are also observed between envelope glycoproteins 
associated with HCVpp and HCVcc. Indeed, differences in the glycosylation profiles were 
observed between HCVpp and HCVcc, suggesting that the accessibility of HCV glycans to 
Golgi glycosidases and/or glycosyltransferases is not the same for the two types of particles, 
due to differences in the assembly process. Furthermore, HCVcc-associated E1 and E2 
envelope glycoproteins form large covalent complexes stabilized by disulfide bridges [32], 
whereas mainly non-covalent E1E2 heterodimers are found to be associated with HCVpp 
[33]. It has also to be pointed out that a higher degree of heterogeneity has also been observed 
in the envelope glycoproteins associated with HCVpp [34]. 
 
 
2.1 Characterization of HCV entry factors with HCVpp and HCVcc systems 
HCVpp have been extensively used for the characterization of HCV-specific host 
entry factors. Cellular entry factors like tetraspanin CD81 [35] and scavenger receptor class B 
type I (SR-BI) [36], previously identified by a biochemical approach using a truncated form 
of E2 as a bait, were confirmed to play a functional role in HCV entry with the help of 
HCVpp [37-38]. Later on, these entry factors were also confirmed with the HCVcc system [2, 
3, 39]. HCVpp were also used in different large-scale screening approaches to identify new 
entry factors. Thanks to these screenings the tight-junction proteins claudin-1 [40] and 
occludin [41] were identified and characterized as essential players during the entry process. 
More recently, with the help of HCVpp, E-cadherin was shown to be an additional HCV-
specific host entry factor [42]. Since its entry functions are uncoupled from other steps of the 
HCV life cycle, HCVpp have also been a major tool to confirm the role of novel HCV-
specific host entry factors identified using the HCVcc system, as shown for the transferrin 
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receptor 1 [43], the VLDL receptor [44], as well as the epidermal growth factor receptor 
(EGFR) and ephrin receptor A2 (EphA2) [45]. 
In contrast, some HCV-specific host entry factors could not be confirmed in the 
HCVpp system. This is the case for Niemann-Pick C1-like 1 (NPC1L1) [46] and serum 
response factor binding protein 1 (SRFBP1) [47]. The lack of HCVpp dependence on these 
HCV-specific host entry factors could be explained by differences in virion composition 
between HCVpp and HCVcc. Indeed, as discussed above, infectious HCV particles are 
associated with lipoproteins and contain neutral lipids and apolipoproteins that can potentially 
play a role during the entry process. Since they are not associated with these host components, 
HCVpp cannot be used to validate the functions of these host factors in HCV entry. For 
instance, due to the role of ApoE in virion attachment to heparan sulfate proteoglycans on 
host cells [48, 49], HCVpp cannot be used to study the early steps of virus entry. Similarly, 
the role of the low density lipoprotein receptor (LDL-R) could not be investigated with the 
HCVpp model [50]. Investigators need therefore to be aware of this major limitation when 
studying HCV entry.  
 
2.2 Characterization of HCV E1E2 envelope glycoprotein functions with HCVpp 
and HCVcc systems 
In addition to their contribution to the characterization of HCV-specific host entry 
factors, HCVpp have also often been used to investigate HCV envelope glycoprotein 
functions. Since these proteins are produced from a plasmid expressing only E1 and E2 
envelope glycoproteins, site-directed mutagenesis can be easily performed and a large number 
of mutants can be simultaneously investigated. HCVpp have indeed been extensively used to 
characterize functional regions in HCV envelope glycoproteins (reviewed in [51]). Another 
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interesting aspect in using HCVpp for the characterization of HCV envelope glycoproteins is 
that mutations introduced by site-directed mutagenesis are stable, whereas in the context of 
HCVcc reversion or second-site mutations can potentially appear. It is worth noting that the 
entry functions of glycoprotein mutants having a defect in virion assembly cannot be 
investigated in the HCVcc system, however some of them can be investigated with the help of 
HCVpp [52]. One needs however to be careful in the interpretation of phenotypes observed 
with HCVpp. For instance, glycosylation mutants that are infectious in the HCVcc system are 
not necessarily functional in the HCVpp model [53]. 
One limitation in investigating the functional role of the viral envelope glycoproteins 
with the HCVpp and HCVcc systems is that not all the envelope proteins from patient isolates 
are functional in these systems. Furthermore, in a recent study, no correlation in relative 
specific infectivity of E1E2-matched HCVcc and HCVpp was observed [31]. This might in 
part be due to different amounts of E2 on HCVcc virions compared to HCVpp, as well as the 
presence of ApoE on HCVcc and not on HCVpp [31]. It has been suggested that multiple 
technical factors can influence production of functional HCVpp, including plasmid 
transfection ratios and use of either MLV or HIV reporter constructs [54]. 
An interesting approach that is often used to study the function of viral envelope 
glycoproteins consists in propagating the virus in serial passages in the presence of an entry 
inhibitor. This method has been successfully used to identify functional regions in HCV 
envelope glycoproteins [55–57]. However, this type of approach can only be performed with 
HCVcc. Similarly, HCVcc adapted to alternative receptors can also be selected to identify 
cross-talks between HCV envelope glycoproteins and receptors [58, 59]. 
 
2.3 Characterization of antibody neutralization with HCVpp and HCVcc systems 
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The presence of E1 and E2 at the surface of HCVpp is compatible with the 
characterization of neutralizing antibodies targeting the two glycoproteins [8, 60] as well as 
cross-neutralizing antibodies [6, 38, 61-62]. Recently, large panels of HCVpp have been 
produced that encompass more of the diversity of circulating HCV variants, which is critical 
for accurate measurement of antibody neutralizing breadth [54, 63]. 
When the HCVcc model was developed, one of its major limitations to study antibody 
neutralization was the lack of HCV sequence diversity available. However, lately, chimeric 
full-length viruses, which express diverse E1E2 variants in the context of JFH1-based genome  
background, have been produced [64–66]. Such panels of HCVcc expressing E1E2 from 
multiple genotypes have been used to measure neutralizing breadth of broadly neutralizing 
monoclonal antibodies [67, 68]. More recently, full-length infectious clones from other 
genotypes have also been developed. They include genotype 1a [69-70], genotypes 2b [71] 
and genotype 3a [72]. These viruses could also be used for the characterization of the 
neutralizing antibody response. More importantly, they will be essential for the analysis of 
genotype differences in terms of sensitivity to antivirals. 
Very recently, Wasilewski and coworkers generated panels of E1E2-matched HCVcc 
and HCVpp to compare sensitivity to neutralizing antibodies [31]. Interestingly, they 
observed a very strong positive correlation between relative neutralization resistance of these 
same E1E2-matched HCVcc and HCVpp variants, indicating that both systems can be used 
for the characterization of neutralizing antibodies. However, the HCVpp system is more 
flexible for this type of study. Comparisons between the two models also showed that HCVpp 
have a tendency to be more sensitive than HCVcc to antibody neutralization [31, 54]. This 
quantitative difference in HCVpp and HCVcc neutralization may be explained by the 
observation that ApoE increases HCVcc neutralization resistance [73]. 
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When studying antibody neutralization, it is important to assess viral evolution in the 
presence of specific monoclonal antibodies to determine their potency to prevent the 
formation of escape variants. However, this can only be performed with the HCVcc system 
which allows the virus to be serially passaged in the presence of antibodies [74]. In the same 
line, the HCVcc system can also be used to identify mutations leading to neutralization escape 
[75]. An additional advantage of the HCVcc system is that the viral particles produced are 
infectious in uPA-SCID mice transplanted with human hepatocytes, chimpanzees [30] and 
genetically humanized mice [76, 77]. This makes them better tools to study antibody 
neutralization in pre-clinical models [62, 78].  
 
 
 
3 Comparison between HCVpp and HCVcc in terms of production and biosafety 
In addition to all the aspects described in the previous paragraphs, these two viral 
models present some differences concerning their production both in terms of quantity of 
virion produced and biosafety level for their manipulation. 
As previously described, HCVpp are generated by a single co-transfection of three 
different plasmids. This represents a limitation in the quantity of pseudoparticles that can be 
produced. In fact, the concomitant presence of the three plasmids in the same cell and their 
respective expression are necessary for assembly and release of HCVpp. Conversely, HCVcc 
virions can be produced in stocks with higher titers than HCVpp, since they can be generated 
by propagating them in serial passages of infected cells rather than by a single transfection 
step (Figure 1).  
On the other hand, even if it can be a limitation in terms of quantity, the lack of 
generation of a complete viral cycle for HCVpp represents an advantage in terms of biosafety. 
Specifically, the lack of HCV genome in HCVpp makes the safety level for manipulation less 
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strict for HCVpp than HCVcc. As a consequence, the European legislation authorizes to 
handle HCVpp in a BSL2 facility, whereas experiments with HCVcc need to be performed in 
a BSL3 laboratory. To circumvent this problem, one can use a system that supports particle 
production based on trans-packaging of subgenomic viral RNA which produces virus-like 
particles that are similar to HCVcc virions [79]. 
In summary, HCVpp can be produced and handled in a BSL2 facility with a limited 
quantity of particles produced, while HCVcc can be produced and amplified to reach higher 
titers, but in more stringent biosafety conditions. 
 
4 Conclusions 
The establishment of HCVpp and HCVcc systems radically changed the study of the 
HCV life cycle and represented major advances to investigate virus-host interactions at the 
cellular level. These two models represent complementary techniques (Table 1) for the study 
of HCV entry and were extensively used during the past decade for the identification of 
cellular entry receptors, the characterization of E1E2 glycoproteins and the study of 
neutralising antibodies (Table 1). It is worth noting that besides these investigations, HCVcc 
have also been extensively used to study HCV genome replication and assembly. When using 
HCVcc and HCVpp systems, one needs to keep in mind that the virion composition of these 
two models is different due to the association of HCVcc particles with lipoproteins. As a 
consequence, experiments performed with these two models can sometimes lead to divergent 
results. However, in the context of antibody-mediated virus neutralization, the two models 
seem to produce similar results [31]. 
In summary, albeit HCVcc represents a more complete tool to study the whole HCV 
life cycle, HCVpp still represent a useful system to investigate the entry steps directly 
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depending on E1 and E2 glycoproteins in a simpler and easier way. The complementary use 
of these two models represents thus a powerful approach for the characterization of the 
complex HCV entry steps. 
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FIGURE 1. HCVpp. HCVpp are produced through the co-transfection of 293T cells with 
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three plasmids respectively coding for the HIV or MLV gag-pol, the reporter gene Firefly 
Luciferase and HCV glycoproteins E1 and E2 from a specific genotype. The co-transfection 
drives the assembly of pseudoparticles constituted by a viral capsid containing the mini-
genome coding for the reporter gene and an envelope in which are inserted the HCV 
glycoproteins. These pseudoparticles are released by the cells and can be collected and used 
to infect permissive cell lines, allowing the quantification of the entry process through 
measurement of the reporter gene activity. HCVcc. A plasmid coding for the HCV cDNA is 
transcribed in vitro thanks to the presence of a T7 RNA polymerase promoter. The 
synthesized HCV RNA is then electroporated in hepatoma cells (Huh-7 or Huh-7.5 cells), 
giving rise to the translation of all the viral proteins and to the generation of a complete 
infection cycle. The virions secreted can be collected and used to infect new hepatoma cells. 
Sequential passages of the supernatant on new permissive cells enable the amplification of the 
virus and the increase of the viral titre. 
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TABLE 1. HCVpp and HCVcc properties 
* According to the European Union legislation 
 
 HCVpp HCVcc 
VLDL/LDL association No Yes 
Apolipoprotein association No Yes 
E1 and E2 envelope 
glycoproteins  Non-covalent E1E2 heterodimers 
Large covalent complexes stabilized 
by disulfide bridges 
Degree of heterogeneity in 
E1E2 High Low 
Study of E1E2 glycoproteins Entry  Entry, assembly and secretion 
Stability of mutations Stable Possibility of reversion or second-site mutation 
Characterization of entry 
factors E1E2-dependent interactions 
E1E2-dependent interactions 
Lipid receptors and apolipoprotein-
dependent interactions 
Selection of E1E2 adaptation 
to alternative receptors No Yes 
Selection of drug-resistant 
variants No Yes 
Selection of neutralization 
escape mutants No Yes 
Sensitivity to antibody 
neutralization Highly sensitive Sensitive 
Study of antibody 
neutralization in animal 
models  
No Yes 
Viral production Limited to one co-transfection Can be amplified by sequential passages in cell culture 
Biosafety level* BSL2 BSL3 

